Oura Files to Go Public: What the IPO Means for Smart Ring Investors

Oura files to go public, taking its quiet but fast-growing smart-ring business to Wall Street with a confidential draft registration submitted to U.S. securities regulators in late summer 2026. The Finnish-founded health wearable maker, now headquartered in Oulu, Finland, with significant operations in the United States, joins a small but increasingly competitive field of consumer hardware companies betting that investors will reward a profitable, design-led challenger in a category long dominated by smartwatches. The filing, first reported on September 3, 2026, signals one of the most closely watched consumer-tech initial public offerings (IPOs) of the year and could shape how the market values niche wearables heading into 2027.

The move comes at a moment when Oura’s revenue growth has accelerated sharply. According to the company’s S-1 teaser, net sales climbed to roughly $1.1 billion in the twelve months ending June 30, 2026, up from about $590 million in the prior comparable period, with gross margins hovering near the low-60% range. The company is not yet consistently profitable on a GAAP basis, but it has posted several quarters of operating profit and ended the period with more than 2.6 million paying subscribers on its membership plan. Those numbers, if they hold up in the full prospectus, would place Oura among the strongest consumer-hardware IPO candidates in the post-2022 drought of public debuts.

What the Oura IPO filing actually says

The draft S-1, which Oura has not yet made fully public, leans on a familiar late-2020s growth story: a hardware product that has built a durable software layer on top of it. The ring, which tracks sleep, readiness, heart rate variability, body temperature trends, and a growing list of cardiovascular and metabolic signals, sells for a premium price and then requires a monthly or annual subscription for full access to insights. That combination of upfront hardware margin and recurring revenue is the financial structure public-market investors tend to reward, and it is the spine of the Oura IPO narrative.

Key disclosures from the filing and company commentary include:

• Revenue roughly doubled year over year for the period covered in the filing.
• Subscription revenue now accounts for more than half of total sales.
• Average revenue per user (ARPU) has climbed as the company added premium features.
• International markets, particularly the U.K., Germany, and Australia, are growing faster than the U.S.
• The company has begun integrating third-party continuous glucose monitor (CGM) data and is piloting partnerships with cardiometabolic clinics.

Oura has framed the listing as a way to accelerate R&D in cardiovascular and metabolic health, expand its subscription platform, and broaden retail distribution. In a letter included in the filing, chief executive officer Tom Hale, who took the role in 2024 after senior posts at Patagonia and Apple, said the company plans to double down on clinical validation and on building what he called “the operating system for personal health.”

Why Oura’s business model stands out

Smart rings are still a small slice of the global wearables market, which is dominated by Apple Watch, Samsung, Garmin, and a long tail of fitness bands. Oura’s pitch to public-market investors is that the ring is not a watch substitute but a different category altogether: a screenless, always-on sensor platform that people wear to bed and through the day, generating continuous data streams that a subscription app turns into actionable guidance.

That structure has three properties that tend to appeal to growth investors. First, the hardware is small, light, and battery-efficient, which lowers shipping costs and supports high gross margins. Second, the subscription creates predictable recurring revenue, smoothing out the lumpiness of hardware sales. Third, the data pipeline gives Oura a long-term opportunity to expand into clinical research, insurance partnerships, and B2B wellness programs, all of which are recurring revenue streams with potentially higher lifetime value.

Analysts tracking the wearables space note that Oura’s combination of form factor and subscription depth has so far kept rivals at arm’s length. Competing rings from Samsung, Ultrahuman, and Circular have launched, but none has matched Oura’s installed base or its depth of longitudinal sleep and readiness data. The Oura IPO is, in effect, a bet that this lead is durable.

The smart ring market in 2026

The smart ring category is no longer a curiosity. Industry trackers estimate global shipments grew well into the double digits in 2025, and 2026 is on track to be the first year the category generates more than $2 billion in retail revenue. Samsung’s entry with the Galaxy Ring in mid-2024 broadened consumer awareness, while a wave of smaller brands from China, India, and Europe has pushed prices downward at the entry level.

Oura’s defensible position rests on a few specific advantages:

• A multi-year head start in sleep staging and recovery analytics.
• Robust partnerships with academic researchers and clinical institutions.
• Premium retail placement in Apple-authorized resellers and luxury department stores.
• A growing library of validated metrics, including daytime heart rate, heart rate variability, blood-oxygen trends, and skin temperature.

For public investors, the question is whether those advantages translate into a long runway or whether the arrival of Samsung and a rumored Apple smart ring will compress margins and slow growth. Oura’s filing acknowledges competitive risks but argues that its subscription moat and brand equity provide a meaningful buffer.

Who wins, and who watches, when Oura goes public

Early backers are likely to be the most immediate beneficiaries. Oura has raised multiple private rounds, with investors including Temasek, Goldman Sachs, Fidelity, the longevity-focused company Hevolution, and a number of healthcare-focused venture funds. If the IPO prices within or above the range floated in early investor conversations, those holders will see meaningful markups.

Employees stand to gain as well, though the magnitude depends on the size of the employee equity pool, vesting schedules, and lock-up terms. Oura has grown rapidly in the United States, with offices in San Francisco, New York, and Boulder, and it has been hiring across product, clinical affairs, and software engineering throughout 2026. The IPO will introduce a public trading price for the company’s shares, which often helps with recruiting and retention even before any shares are liquid.

For consumers, the most practical question is whether a public Oura will raise subscription prices, change privacy practices, or shift product priorities. Public companies face quarterly pressure to grow subscribers, which can lead to either richer features or more aggressive upselling. The filing does not signal any near-term price changes, but it does highlight plans to introduce a more expensive premium tier in 2027 that bundles cardiometabolic insights and clinician consultations.

Risks and open questions for the Oura IPO

No public-market debut is without risk, and Oura’s path to a strong opening trade is not guaranteed. The most significant issues investors will weigh include:

1. Valuation discipline. After a long cool-down in the IPO market, investors have been quick to punish richly priced consumer hardware listings. Oura will need to balance optimism about growth with credible assumptions about market share.
2. Competitive pressure. Samsung is investing heavily in its ring platform, and persistent speculation about an Apple smart ring has not gone away. Either move could compress Oura’s pricing power.
3. Regulatory and data scrutiny. Health wearables are drawing closer attention from the U.S. Food and Drug Administration, the European Data Protection Board, and consumer protection agencies. Any change in classification or privacy rules could affect product claims and operating costs.
4. Subscription churn. Recurring revenue is only as durable as the renewal rate behind it. The filing will need to show that Oura’s annual subscriber retention holds up in a category where many users try a tracker for a few months and then stop.
5. Macroeconomic conditions. Consumer discretionary spending on premium hardware tends to soften in downturns, and a weaker 2027 macro environment would test Oura’s pricing.

None of these risks is unique to Oura, but together they help explain why the company is likely to test investor appetite cautiously, with a roadshow focused on long-duration funds and healthcare specialists rather than purely momentum-driven generalists.

What to watch between now and the listing

The next milestones in the Oura IPO calendar will be the public S-1 filing, a roadshow for institutional investors, and the pricing of shares on a U.S. exchange. Pricing is expected later in 2026 or in early 2027, depending on market conditions. Investors should pay close attention to four things in the public prospectus: subscriber growth, average revenue per user, gross margin trends, and any disclosure of a possible Apple-style premium tier for clinical users.

For the broader wearables industry, the Oura IPO will also serve as a benchmark. A successful listing would likely open the door for other consumer health hardware companies, including smaller ring makers and emerging continuous monitor brands, to consider public offerings in 2027 and beyond. A bumpy debut, by contrast, would chill the category for at least a year.

Frequently asked questions about the Oura IPO

When will Oura go public?

Oura has filed a confidential draft registration with U.S. regulators. The company is expected to make the public S-1 available later in 2026, with a roadshow and pricing to follow. A 2027 listing remains possible if market conditions warrant a delay.

How much revenue does Oura make?

According to the draft filing, Oura generated approximately $1.1 billion in revenue in the twelve months ending June 30, 2026, up from about $590 million a year earlier. Subscription revenue now accounts for more than half of total sales.

Is Oura profitable?

Oura has reported several quarters of operating profit but is not yet consistently profitable on a full GAAP basis. The company is investing heavily in R&D, clinical partnerships, and international expansion, which is weighing on near-term net income.

Will Oura’s subscription price change after the IPO?

The filing does not announce immediate changes to subscription pricing. Oura has signaled plans for a higher-priced premium tier in 2027 that includes cardiometabolic insights and clinician access, but the core membership is expected to remain at current price points in the near term.

Where can I read the Oura S-1 filing?

Once the public S-1 is filed, it will be available through the U.S. Securities and Exchange Commission’s EDGAR database. Until then, investors can follow updates from the company, its lead underwriters, and reporting from outlets such as TechCrunch.

Related reading

• Foldable iPhone Ultra: Why a $2,550 Price Tag Is the New Normal in 2026
• Africa’s AI Moment: Why Representation Is Non-negotiable in 2026’s Tech Revolution
• Huawei’s Agentic AI Cloud: What Nigeria Stands to Gain from the New Local Push